164 related articles for article (PubMed ID: 9509296)
1. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
2. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
4. Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin.
Teicher BA; Maehara Y; Kakeji Y; Ara G; Keyes SR; Wong J; Herbst R
Int J Cancer; 1997 Mar; 71(1):49-58. PubMed ID: 9096665
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
6. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
7. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
8. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
9. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
10. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
11. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
Chen G; Teicher BA; Frei E
Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta in in vivo resistance.
Teicher BA; Holden SA; Ara G; Chen G
Cancer Chemother Pharmacol; 1996; 37(6):601-9. PubMed ID: 8612316
[TBL] [Abstract][Full Text] [Related]
13. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
[TBL] [Abstract][Full Text] [Related]
14. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
15. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
16. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
17. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
18. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI.
Kummar S; Ishii A; Yang HK; Venzon DJ; Kim SJ; Gress RE
Biol Blood Marrow Transplant; 2001; 7(1):25-30. PubMed ID: 11215695
[TBL] [Abstract][Full Text] [Related]
19. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
20. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]